Get the Latest Funding and Biotech News

Cancentus joins BaseLaunch portfolio

We’re excited to have Cancentus join our portfolio. Cancentus, a spin-off from the University of Geneva and the University of Basel, is exploiting oncogene-induced DNA…

Lonza renews partnership with BaseLaunch

Building on a strong collaboration, Lonza and BaseLaunch have renewed their partnership to further support the development of innovative therapeutics. As a Domain Partner, Lonza…

Anaveon Appoints Thaminda Ramanayake as CEO

Basel, Switzerland, March 23, 2026 – Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of…

Vossius renews partnership with BaseLaunch

We are delighted to announce that Vossius is continuing its partnership with BaseLaunch to support cutting-edge early-stage biotechs in protecting and strengthening their innovations, helping…

Umlaut.bio joins BaseLaunch portfolio

We’re excited to welcome Umlaut.bio to our portfolio. Umlaut.bio, a spin-off from EMBL in Heidelberg, is pioneering the development of small molecules inhibiting tRNA modifications…

FimmCyte Announces Collaboration with Gedeon Richter

Basel, February 18th, 2026 - FimmCyte AG (“FimmCyte”), a pioneering Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases, announces a strategic research collaboration and…

Pfizer becomes a BaseLaunch partner

Basel, Switzerland - February 10, 2026 — BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, announced today the…

We welcome Catalent as our new domain partner

We are pleased to announce a partnership with Catalent, Inc., a global contract development and manufacturing organization (CDMO) supporting pharmaceutical, biotech and consumer health companies…

Takeda becomes a BaseLaunch partner

Basel, Switzerland - December 16, 2025 — BaseLaunch, a platform to launch, fund, and build early biotech ventures developing cutting-edge therapeutics, announced today Takeda has…

Aukera Therapeutics Comes Out of Stealth

Basel, Switzerland - 11 December 2025, Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel is officially coming out of stealth as it enters…

Gibela Publishes New Findings on CNNM4 in Metabolic Disease

Basel, Switzerland - 14 November 2025, Gibela Therapeutics GmbH (“Gibela”), the Basel-based Biotech focusing on the treatment of liver diseases using siRNA technology to target…

Tolremo Announces Positive TT125-802 Results at ESMO 2025

Basel, Switzerland - October 17, 2025, TOLREMO therapeutics AG (TOLREMO) today announced encouraging clinical data from 34 patients with advanced solid tumors treated with TT125-802…

Alentis appoints Dr. Mark Pruzanski as CEO

Basel, Switzerland – Oct 15, 2025, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology…

Synendos Reports Positive Phase 1 Results for SYT-510, Preparing for Phase 2

Basel, Switzerland - September 24, 2025, Synendos Therapeutics (“Synendos”), the clinical-stage biotech company developing breakthrough therapies for neuropsychiatric disorders, announced today topline results for its…

metaLead Therapeutics Appoints David Urech as Member of the Board of Directors

Basel, Switzerland – September 23, 2025 – metaLead Therapeutics AG (“metaLead”) announces the appointment of David Urech, PhD, Founder and former Chief Executive Officer of…

Gibela publishes groundbreaking research in Hepatology

We are pleased to share that the research of Gibela Therapeutics, our portfolio company, was featured on the cover of the Hepatology journal. The company is…

Synendos Appoints Dr. George Garibaldi as Chief Medical Officer

Basel, Switzerland – Synendos Therapeutics, the clinical-stage biotechnology company developing breakthrough therapies for neuropsychiatric disorders, announced the appointment of Dr. George Garibaldi as Chief Medical…

We welcome BioDuro as our new domain partner

We’re excited to share our new partnership with BioDuro, a trusted CRDMO with a 29-year proven track record and strong reputation for delivering high-quality, end-to-end…

BaseLaunch Summer Get-Together 2025

Our summer get-together brought people from across the biotech ecosystem, from founders and scientists, to investors, partners, and beyond, for an evening that combined meaningful…

Phialogics AG announces the appointment of Dr. Debra Barker as Chief Medical Officer

Allschwil, Switzerland – 10 June, 2025 – Phialogics AG announces the appointment of Dr. Debra Barker as Chief Medical Officer. Dr. Barker joins Phialogics with…

Hemastatx joins BaseLaunch portfolio

We’re excited to welcome Hemastatx to our portfolio. Hemastatx, a spin-off from KU Leuven, has emerged from stealth with funding from BaseLaunch, Gemma Frisius Fund and…

metaLead secures CHF 1 million investment to advance novel therapy for Wilson disease

Basel, Switzerland – May 5, 2025 – metaLead Therapeutics AG (metaLead), a pioneering biotech company developing next-generation metal-binding therapies, announced today that it has secured…

Ilonov joins BaseLaunch portfolio

Ilonov is harnessing groundbreaking discoveries to revolutionize treatment for metabolic disorders. By harvesting novel targets discovered from breakthrough research on the human muscle secretome, the…

Phialogics appoints Dr. Natalia Novac as Chief Executive Officer

Basel, Switzerland – 10 Feb, 2025, Phialogics AG has announced the appointment of Dr. Natalia Novac as Chief Executive Officer. Natalia has a great experience…

Gibela Therapeutics joins BaseLaunch portfolio

Gibela Therapeutics, a spin-off from the Cooperative Research Center in Biosciences (CIC bioGUNE), is pioneering RNA-based therapeutics for the treatment of liver diseases. The company,…

Alentis announces positive topline results from two studies of Lixudebart

Basel, Switzerland – 9 Jan, 2025, Alentis Therapeutics, a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced positive topline…

Anaveon appoints Dr. Richard Sachse as Chief Medical Officer

Basel, Switzerland – 18 Dec, 2024, Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Richard Sachse, M.D., Ph.D., as Chief Medical Officer…

Stromal publishes groundbreaking research in Cell

We are pleased to share that Stromal Therapeutics have published groundbreaking research in Cell, shedding light on a critical interplay between fibroblasts and the local…

Cimeio Therapeutics signs $300M partnership with Kyowa Kirin

Basel, Switzerland and Cambridge, MA – 9 Dec, 2024, Cimeio Therapeutics announced that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa…

metaLead joins BaseLaunch portfolio

MetaLead Therapeutics AG, a spin-out from the University of Zurich, is pioneering the field of metal-related diseases by focusing on novel therapeutic approaches for conditions…

Alentis Therapeutics raises $181.4 million in an oversubscribed series D financing

Basel, Switzerland – 12 Nov, 2024, The BaseLaunch portfolio company Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and…

Synendos secures Innosuisse funding to advance clinical development of SYT-510

Synendos AG, a BaseLaunch portfolio company, has been awarded a prestigious grant under the Start-Up Innovation Project (SIP) scheme by Innosuisse. This highly competitive initiative…

Alentis Therapeutics receives FDA IND clearance for ALE.P02, a novel CLDN1-ADC for the treatment of squamous cancers

Basel, Switzerland – 2 Oct, 2024, Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced yesterday…

MT-act joins BaseLaunch portfolio

MT-act spun out from the Institute of Human Genetics and CNRS in Montpellier, leverages recent advances in understanding cytoskeleton stiffness and its influence on age-related…

We welcome Hoffmann & Partner as our new domain partner

We’re pleased to announce a partnership with Hoffmann & Partner AG, a well-regarded firm specializing in mergers & acquisitions (M&A) and CFO services. With over…

BaseLaunch summer get-together 2024

We were pleased to have so many experts, partners, and friends joining the BaseLaunch Summer get-together on Wednesday last week. It was a great opportunity…

NXI Therapeutics extends pre-seed funding to CHF 3.5 million ahead of major seed round

NXI Therapeutics AG, developer of tomorrow’s disruptive immunotherapies by coronin 1 modulation, today announces the extension of a pre-seed financing totalling to 3.5 million CHF.…

Nature publication demonstrating Cimeio`s transformative approach towards blood cancers

Cimeio Therapeutics today announced a publication in Nature showing that its CD45 antibody-drug conjugate (ADC) eradicated aggressive leukemic cells in vivo, while hematopoiesis was fully preserved and…

AbbVie becomes a BaseLaunch partner

AbbVie joins other pharmaceutical, venture fund and biotechnology partners supporting BaseLaunch’s company creation endeavours. BaseLaunch’s mission is to help scientists and entrepreneurs build exceptional biotech…

Alentis appoints Alberto Toso Chief Scientific Officer

Basel, Switzerland – 29 April, 2024, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today…

Our partnership with CSL

BaseLaunch is excited to announce the extension of the partnership with CSL, a global biotech leader. Together, we're committed to driving innovation in healthcare. CSL’s…

We welcome VISCHER as our new domain partner

We are pleased to announce a partnership with VISCHER, a respected Swiss law firm known for its commitment to providing startups, entrepreneurs and investors with…

KPMG renews partnership with BaseLaunch

We are delighted to announce that KPMG, is continuing its partnership with BaseLaunch to help support cutting-edge early-stage biotechs to achieve financing and grow their…

FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund

FimmCyte, a pioneering women's health biotech, announces an investment of 1 million CHF as a convertible loan from the UZH Life Sciences Fund (LSF). FimmCyte’s…

Synendos Therapeutics granted EMA clinical trial authorisation

BASEL, Switzerland, 18 January 2024 - Synendos Therapeutics AG, a world leader in innovative Endocannabinoid System (ECS) treatments, today announces that it has received approval…

William Pao joins Alentis Therapeutics as independent board member

Basel, Switzerland – Alentis Therapeutics , a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today that Dr. William…

Novo Nordisk becomes a BaseLaunch partner

Novo Nordisk has become the latest partner to join BaseLaunch. Novo Nordisk joins other world-class pharma, venture fund and biotechnology partners - Roche, Johnson &…

Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM

Basel, Switzerland, 13 December, 2023 – Engimmune Therapeutics AG (“Engimmune”), a world-class developer of soluble T-cell receptor drugs (‘TCRs’) to treat solid tumours, is pleased…

Ferring and PharmaBiome enter a collaboration and exclusive licensing agreement

Ferring Pharmaceuticals and PharmaBiome announced a research & development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. The deal provides Ferring…

TOLREMO treats first patient in phase I trial with TT125-802, a novel therapeutic agent to overcome transcriptional cancer drug resistance

TOLREMO today announced that the first patient has been dosed in its first-in-human clinical trial evaluating the safety and tolerability, pharmacokinetics, and pharmacodynamics of its…

T3 Pharma acquired by Boehringer Ingelheim for up to 450M Swiss francs

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma. Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharma…

FDA clears Versameb’s VMB-100 for stress urinary incontinence treatment

Versameb AG, a leading pre-clinical stage biotechnology company, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND)…

Alentis Therapeutics doses first patient in phase 1/2 clinical trial of ALE.C04

This first-in-human study evaluates the safety, tolerability and efficacy of ALE.C04 as a monotherapy and in combination.Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company within our portfolio…

FimmCyte announces the appointment of Dr. Markus Kalousek as chairperson

Dr. Markus Kalousek takes on the role of Chairperson at FimmCyte, a pioneering women's health biotech, starting from 1 Nov 2023. With over 25 years in…

Onena Medicines secures 3.7 M Swiss francs investment

Onena Medicines closes 3.7M CHF funding round to advance its novel DSIP targeting antibody portfolio.Onena Medicines AG, a cellular reprogramming platform drug discovery company, announced…

Johnson & Johnson Innovation renews its commitment

We are delighted to announce that Johnson and Johnson is continuing its partnership with BaseLaunch to help support cutting-edge early-stage biotechs to achieve financing and…

Cimeio collaborating with the University of Pennsylvania

Cimeio Therapeutic, headquartered in Basel with a subsidiary located in Cambridge, Massachusetts, is to carry out further research and evaluate its novel, universal immunotherapy for…

Salvina Therapeutics joins BaseLaunch portfolio

Salvina Therapeutics AG, a recently founded Swiss company, is developing new therapies to break efficacy ceilings in inflammatory and autoimmune diseases. The company has unlocked…

TOLREMO therapeutics secures USD 39 million

Basel, 20 September, 2023 – The Swiss biotech company TOLREMO therapeutics AG recently completed a successful Series A financing, bringing the total amount raised to…

Alentis Therapeutics receives FDA Fast Track Designation for ALE.C04

We are pleased to announce that Alentis Therapeutics, a company within our portfolio, has been granted fast track designation by the US FDA for its…

BaseLaunch Summer Get-Together 2023

We are very pleased to have had so many experts, partners, and friends joining our Summer Get-together this year! It was an incredible day filled…

Versameb strengthens its Board of Directors

Versameb, transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD,…

Cimeio Therapeutics and Prime Medicine announce research collaboration

Our portfolio company, Cimeio Therapeutics, a biotechnology company that is reinventing cell therapy through its leadership in the emerging field of epitope shielding, and Prime…

Phialogics AG appoints Prof. Dr. Erich Schlick as Chairman of its Board of Directors

Phialogics AG has announced the appointment of Prof. Dr. Erich Schlick as Chairman of its Board of Directors. Erich was introduced to Phialogics by BaseLaunch…

Phialogics closed a €600k pre-seed financing round with HTGF

Our portfolio company, Phialogics - a preclinical stage company developing cell-type-specific immune checkpoint activators to prevent multi-organ failure in autoimmune diseases, closed a €600k pre-seed…

Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

Engimmune Therapeutics, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has announced the appointment of Dr. Lars Nieba as Chief Executive Officer. Engimmune…

BaseLaunch Portfolio has raised over half a billion dollars to date!

We are delighted to announce that our portfolio has blown past half a billion dollars raised to now collectively reach over $550M! Just the last…

Alentis Therapeutics closes $105M funding round Led by Jeito Capital, Novo Holdings and RA Capital Management

Alentis Therapeutics is a thriving clinical-stage biotech company in Basel, Switzerland, developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. The company, lead by…

FimmCyte joins BaseLaunch Portfolio

Endometriosis is a painful and debilitating condition that affects one in every ten women. Despite being a common health issue, there are currently limited treatment…

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

NXI Therapeutics (formerly Nextimmune), the specialist biotech developing next generation immunosuppressive drugs for autoimmune diseases and organ transplantation, today announces that it has appointed Dr…

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

Anaveon, a clinical-stage immuno-oncology company, announced updated clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as…

BaseLaunch and WuXi Biologics announce their partnership

We are pleased to announce the partnership between BaseLaunch and WuXi Biologics! WuXi Biologics is a global Contract Research, Development and Manufacturing Organization with operations…

Phialogics joins BaseLaunch Portfolio

We are excited to welcome Phialogics as our newest portfolio company! Basel, Switzerland. 20 September 2022 - Phialogics is a preclinical stage company developing cell-type-specific…

Roivant’s growth story

Want to know how to grow a global biopharma company from scratch into a leader in their field? Read about the key insights from our…

BaseLaunch and Schrödinger announce their partnership

We are pleased to announce the partnership between BaseLaunch and Schrödinger! A pioneer in pharmaceutical software, Schrödinger was founded in 1990. The company’s mission to…

BaseLaunch’s Mission: Building Exceptional Biotech Companies

Many factors must come together to see a biotech venture succeed. Unique ideas and exceptional science discoveries are important criteria, as are risk-taking and entrepreneurial…

Charles River announces partnership with BaseLaunch

Charles River Laboratories and BaseLaunch have announced their partnership! With 120 sites around the globe, Charles Rivers is strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving their…

InCephalo AG Announces Appointment of Lauren E. Abrey, MD as Chief Medical Officer

InCephalo AG announces that Lauren E. Abrey, MD will join the company as Chief Medical Officer (CMO). Dr. Abrey will lead the clinical and medical…

How Lonza’s Ibex® Design 2.0 Program Accelerates Time to IND

From DNA to TOX drug substance in 5 months and IND in 11 months. Speed to clinic and to market is increasingly gaining importance among…

Wuxi AppTec partnership with BaseLaunch renewal

In an effort to further grow the flow of innovation centered in the Basel Area, WuXi AppTec and BaseLaunch have renewed their partnership to join forces to help young biopharmaceutical enterprises overcome some of…

Accessing TCR Discovery Capabilities with Alloy Therapeutics

In particular, TCR-based therapeutics hold great promise to improve immunotherapies, as T cells are key players in adaptive immune response leading to curative effects in…

BaseLaunch Summer Get-Toghether 2022

We are very pleased to have had so many experts, partners, and friends joining our Summer Get-together this year! Check below some of our memories…

Lonza announces collaboration with BaseLaunch

Lonza works to enable a healthier world by supporting customers to deliver new and innovative medicines that help treat a wide range of diseases. Their…

Anaveon_-startups_Switzerland-credit-Jasmin-Rei

Anaveon announces starting efficacy trials with ANV419, their powerful and selective IL-2 agonist.

One of our portfolio companies, Anaveon AG, announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419…

Onena Medicines joins BaseLaunch Portfolio

We are excited to welcome Onena Medicines as our newest portfolio company! Onena Medicines is a Swiss-Spanish biotech company emerging from the Chan Zuckerberg Biohub…

Engimmune Therapeutics raises $16.7M in seed financing co-led by Pureos Bioventures and Novo Holdings

Engimmune is a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, founded in August 2021 by Dr. Rodrigo Vazquez-Lombardi, Prof Sai Reddy and Dr…

Cimeio Therapeutics raises a 50M USD series A financing from Versant Ventures

Cimeio therapeutics is a spin-off from the University of Basel. The scientific basis was born out of years of cutting-edge research by Professor Lukas Jeker–co-founder…

BaseLaunch – onwards and upwards

2022 started off on some good notes for BaseLaunch, with two new companies (one still in stealth) joining our portfolio and another one announcing the…

Aukera Therapeutics joins BaseLaunch Portfolio

We are excited to welcome Aukera Therapeutics as our newest portfolio company! Basel, Switzerland., 15 February 2022 — Aukera Therapeutics is a spin-off from the Biozentrum…

Stromal Therapeutics joins BaseLaunch Portfolio

We are excited to welcome Stromal Therapeutics as our newest portfolio company! Basel, Switzerland., 28 January 2022 — Stromal Therapeutics is emerging from one of…

Alentis starts first in-human clinical trial

Alentis Therapeutics starts their first-in-human clinical trial

FDA greenlights Alentis Phase 1 protocol study design Alentis to begin transition from pre-clinical to clinical Basel, Switzerland., 04 January 2022 — Alentis Therapeutics, AG…

Anaveon raises 110 Million Swiss francs in Series B financing

Back in 2017, when we first met Andreas Katopodis, he had the vision to build a company that translates breakthrough science in the field of…

Premier news: KPMG renews its commitment

We are delighted to announce that KPMG, is continuing its partnership with BaseLaunch to help support cutting-edge early-stage biotechs to achieve financing and grow their…

Several of our companies are looking for experienced biopharma talent

"People Wanted: For hazardous journey. Small wages, bitter cold, long months of complete darkness, constant danger, safe return doubtful. Honor and recognition in case of…

Engimmune Therapeutics joins BaseLaunch Portfolio

Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on…

China Medical System joins BaseLaunch as latest partner

We are delighted to announce that China Medical System is now part of the BaseLaunch partner portfolio. This is the first Chinese company to partner…

Expansion of BaseLaunch portfolio of companies 2021

We are proud to announce the recent expansion of our portfolio of companies. We welcome two newcomers - Incephalo and NextImmune - to our family.…

Alentis secures $67 Million US dollars

Looking back, what a journey! We remember well when we first started working with Thomas Baumert in late 2017. Built on many years of transformational…

Swiss Biotech report 2021

Overall, investment in Swiss biotech companies almost tripled on the previous year’s figure. It amounted to 3.44 billion Swiss francs. Investment in research and development…

Synendos Therapeutics expands series A to $25 Million

Synendos is developing first-in-class inhibitors. These inhibitors modulate a newly identified drug target in the body’s endocannabinoid system which is a key neuromodulator system in…